Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Globe Newswire•10/11/2026•07:30 ET
0
Key Highlights
- ➤Ardelyx to participate in a Jefferies Global Healthcare Conference fireside chat November 17, 2026.
- ➤Ardelyx has two U.S.-approved commercial products: IBSRELA and XPHOZAH.
- ➤Ardelyx is developing IBSRELA in Phase 3 for chronic idiopathic constipation.
- ➤RDX10531 is a next-generation NHE3 inhibitor in Ardelyx’s pipeline.
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET.
To access the live webcast of the fireside chat, please visit the Events and Presentations page within the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available following the event.
Get started
Create a free account to read the full story.